Literature DB >> 10075671

The STAT3-independent signaling pathway by glycoprotein 130 in hepatic cells.

C F Lai1, J Ripperger, Y Wang, H Kim, R B Hawley, H Baumann.   

Abstract

Interleukin (IL)-6 is a major regulator of hepatic acute-phase plasma protein (APP) genes. The membrane-proximal 133-amino acid cytoplasmic domain of glycoprotein (gp) 130, containing one copy of the Box3 motif, is sufficient to transmit a productive signal to endogenous APP genes in rat hepatoma H-35 cells. In contrast, a mutant gp130 domain lacking the Box3 motif activates Janus kinases to a normal level but fails to activate signal transducer and activator of transcription 3 and to up-regulate a number of APP genes, including thiostatin, fibrinogen, hemopexin, and haptoglobin. However, in the absence of Box3, gp130 still stimulates the expression of alpha2-macroglobulin and synergizes with IL-1 to up-regulate alpha1-acid glycoprotein. The Box3 motif is not required for activation of the SH2-containing protein tyrosine phosphatase 2 or the mitogen-activated protein kinase (MAPK), nor is the immediate induction of egr-1 and junB significantly altered. Surprisingly, gp130 without any functional Box3 stimulates prolonged activation of MAPK, leading to an extended period of up-regulation of egr-1 and to an extracellularly regulated kinase-mediated reduction in the IL-6-stimulated production of thiostatin. IL-6 reduces proliferation of H-35 cells through signaling by the Box3. In addition, cells expressing Box3-deficient gp130 showed distinct morphologic changes upon receptor activation. Taken together, these results indicate that Box3-derived and Box3-independent signals cooperate in the control of hepatic APP genes and that Box3 may be involved in the modulation of MAPK activity in gp130 signaling.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10075671     DOI: 10.1074/jbc.274.12.7793

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  6 in total

1.  Essential role of STAT3 in the control of the acute-phase response as revealed by inducible gene inactivation [correction of activation] in the liver.

Authors:  T Alonzi; D Maritano; B Gorgoni; G Rizzuto; C Libert; V Poli
Journal:  Mol Cell Biol       Date:  2001-03       Impact factor: 4.272

2.  Targeting STAT3 to Suppress Systemic Pro-Oncogenic Effects from Hepatic Radiofrequency Ablation.

Authors:  Gaurav Kumar; S Nahum Goldberg; Svetlana Gourevitch; Tatyana Levchenko; Vladimir Torchilin; Eithan Galun; Muneeb Ahmed
Journal:  Radiology       Date:  2017-09-06       Impact factor: 11.105

3.  Dual signaling role of the protein tyrosine phosphatase SHP-2 in regulating expression of acute-phase plasma proteins by interleukin-6 cytokine receptors in hepatic cells.

Authors:  H Kim; H Baumann
Journal:  Mol Cell Biol       Date:  1999-08       Impact factor: 4.272

4.  Transformation of human bronchial epithelial cells alters responsiveness to inflammatory cytokines.

Authors:  Gregory M Loewen; Erin Tracy; Frédéric Blanchard; Dongfeng Tan; Jihnhee Yu; Sameera Raza; Sei-Ichi Matsui; Heinz Baumann
Journal:  BMC Cancer       Date:  2005-11-04       Impact factor: 4.430

5.  Defective gp130-mediated signal transducer and activator of transcription (STAT) signaling results in degenerative joint disease, gastrointestinal ulceration, and failure of uterine implantation.

Authors:  M Ernst; M Inglese; P Waring; I K Campbell; S Bao; F J Clay; W S Alexander; I P Wicks; D M Tarlinton; U Novak; J K Heath; A R Dunn
Journal:  J Exp Med       Date:  2001-07-16       Impact factor: 14.307

Review 6.  IL-6 in the Ecosystem of Head and Neck Cancer: Possible Therapeutic Perspectives.

Authors:  Michal Španko; Karolína Strnadová; Aleš Jan Pavlíček; Pavol Szabo; Ondřej Kodet; Jaroslav Valach; Barbora Dvořánková; Karel Smetana; Lukáš Lacina
Journal:  Int J Mol Sci       Date:  2021-10-13       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.